Form 4: CYTK Exec Sells Shares Under 10b5-1 Plan

Cytokinetics EVP of Research & Development, Fady Ibraham Malik, exercised options and sold 2,000 shares of common stock under a pre-arranged 10b5-1 trading plan.

Summary

• Fady Ibraham Malik, EVP Research & Development at Cytokinetics Inc. (CYTK), reported a transaction on October 7, 2025.
• Malik exercised non-qualified stock options to acquire 2,000 shares of common stock at an exercise price of $10.60 per share.
• Concurrently, Malik sold 2,000 shares of common stock at a price of $60.56 per share.
• The transactions were conducted pursuant to a Rule 10b5-1 pre-arranged trading plan.
• Following these transactions, Malik directly beneficially owns 140,610 shares of common stock and 3,105 derivative securities (non-qualified stock options).

Sentiment

Score: 6

Explanation: The transaction reflects an executive realizing profit from vested options, which is generally a neutral to slightly positive sign of executive compensation effectiveness. The 10b5-1 plan mitigates any negative sentiment typically associated with insider sales.

Positives

• The executive realized a significant profit from the option exercise and sale, with shares acquired at $10.60 and sold at $60.56.
• The transaction was executed under a Rule 10b5-1 plan, indicating a pre-scheduled sale rather than a reaction to immediate company news.

Negatives

• The executive's direct beneficial ownership of common stock decreased by 2,000 shares as a result of the sale.

Future Outlook

No forward-looking statements or guidance are provided in this Form 4 filing.

Industry Context

This is a routine insider transaction report and does not provide information directly related to broader industry trends or competitors.

Stakeholder Impact

• Shareholders: Minor, routine dilution from option exercise, offset by the executive's profit realization. The 10b5-1 plan suggests a pre-planned sale, reducing concerns about market timing.
• Employees: Demonstrates the value of executive compensation plans.

Key Dates

Keywords

Cytokinetics, CYTK, Insider Trading, Form 4, Stock Option Exercise, Share Sale, Fady Ibraham Malik, 10b5-1 Plan, Executive Compensation